PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5117-5122

  He, Mao Lin ^a   Wu, Yang ^a,b   Zhao, Jin Min ^a   Wang, Zhe ^a,b   Chen, Ying Bin ^a,b  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Osteosarcoma; PIK3CA; Single nucleotide polymorphisms; Susceptibility

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BONE TUMOR; CASE CONTROL STUDY; CHILD; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; OSTEOSARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CASE-CONTROL STUDIES; CHILD; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; YOUNG ADULT;

EID: 84887594816     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5117     Document Type: Article

References (27)

1. Chen J, Shao P, Cao Q, et al (2012). Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One, 7, e40817.
2. Choy E, Hornicek F, MacConaill L, et al (2012). High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer, 118, 2905-14.
3. Courtney KD, Corcoran RB, Engelman JA (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol, 28, 1075-83.
4. Fendri A, Khabir A, Mnejja W, et al (2009). PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci, 100, 2034-9.
5. Foster L, Dall GF, Reid R, et al (2007). Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br, 89, 1234-8.
6. Fresno Vara JA, Casado E, de Castro J, et al (2004). PI3K/Akt signalling pathway and cancer. Cancer Treat Rev, 30, 193-204.
7. Gorlick R (2009). Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res, 152, 467-78.
8. Hameed M, Dorfman H (2011). Primary malignant bone tumors--recent developments. Semin Diagn Pathol, 28, 86-101.
9. Hildebrandt MA, Yang H, Hung MC, et al (2009). Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol, 27, 857-71.
10. Jiang BH, Liu LZ (2009). PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res, 102, 19-65.
11. Linabery AM, Ross JA (2008). Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer, 112, 416-32.
12. Liu P, Cheng H, Roberts TM, et al (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 8, 627-44.
13. Liu Y, Lv B, He Z, et al (2012). Lysyl oxidase polymorphisms and susceptibility to osteosarcoma. PLoS One, 7, e41610.
14. Liu Z, Hou P, Ji M, et al (2008). Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab, 93, 3106-16.
15. Mure H, Matsuzaki K, Kitazato KT, et al (2010). Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol, 12, 221-32.
16. Nakatani K, Thompson DA, Barthel A, et al (1999). Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem, 274, 21528-32.
17. Qian Y, Corum L, Meng Q, et al (2004). PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol, 286, C153-63.
18. Rosty C, Young JP, Walsh MD, et al (2013). PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One, 8, e65479.
19. Samuels Y, Wang Z, Bardelli A, et al (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 554.
20. Savage SA, Mirabello L, Wang Z, et al (2013). Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet, 45, 799-803.
21. Subbiah V, Kurzrock R (2011). Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol, 23, 352-60.
22. Sung JS, Park KH, Kim ST, et al (2012). Discovery and evaluation of polymorphisms in the AKT2 and AKT3 promoter regions for risk of Korean lung cancer. Genomics Inform, 10, 167-74.
23. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2, 489-501.
24. Wang LE, Ma H, Hale KS, et al (2012). Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol, 138, 377-85.
25. Xing JC, Tufano RP, Murugan AK, et al (2012). Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification. PLoS One, 7, e49192.
26. Xing M (2010). Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid, 20, 697-706.
27. Zhang L, Sun S, Zhou J, et al (2011). Knockdown of Akt1 promotes Akt2 upregulation and resistance to oxidative-stress-induced apoptosis through control of multiple signaling pathways. Antioxid Redox Signal, 15, 1-17.